Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > mBC researcher self-treated with OV now recurrent free

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 19, 2024 9:53pm

140 Views

Post# 36273463

RE:RE: mBC researcher self-treated with OV now recurrent free

This unconventional case finding further confirms ONCY's Phase 2 Bracelet-1 mBC study involving the intravenous administration of pelareorep (monotherapy) + paclitaxel as an effective combination therapy for the treatment of metastatic breast cancer.

The addition of a Fc attenuated PD-(L)1 immune checkpoint inhibitor to the pelareorep + paclitaxel combination would have an enhance positive and synergistic effect in the treatment of both breast AND pancreatic cancers

<< Previous

Bullboard Posts

Next >>

Canopy Growth nears adjusted EBITDA profitability in Q2 2025